BioCardia, Inc. (NASDAQ:BCDA) CEO Purchases $50,129.86 in Stock

BioCardia, Inc. (NASDAQ:BCDA) CEO Peter Altman acquired 26,246 shares of the company’s stock in a transaction that occurred on Wednesday, April 23rd. The stock was bought at an average cost of $1.91 per share, with a total value of $50,129.86. Following the purchase, the chief executive officer now owns 138,966 shares in the company, valued at $265,425.06. The trade was a 23.28 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Peter Altman also recently made the following trade(s):

• On Tuesday, April 15th, Peter Altman purchased 100 shares of BioCardia stock. The stock was acquired at an average price of $2.14 per share, with a total value of $214.00.
• On Thursday, April 10th, Peter Altman acquired 300 shares of BioCardia stock. The shares were purchased at an average price of $1.99 per share, with a total value of $597.00.
• On Monday, April 7th, Peter Altman acquired 500 shares of BioCardia stock. The shares were purchased at an average price of $1.96 per share, with a total value of $980.00.
• On Thursday, April 3rd, Peter Altman bought 1,200 shares of BioCardia stock. The shares were bought at an average cost of $2.24 per share, for a total transaction of $2,688.00.
• On Monday, March 3rd, Peter Altman acquired 500 shares of BioCardia stock. The stock was acquired at an average cost of $2.11 per share, for a total transaction of $1,055.00.
• On Friday, February 7th, Peter Altman purchased 600 shares of BioCardia stock. The shares were purchased at an average cost of $2.48 per share, for a total transaction of $1,488.00.
• On Wednesday, January 29th, Peter Altman bought 500 shares of BioCardia stock. The shares were bought at an average cost of $2.40 per share, with a total value of $1,200.00.

BioCardia Stock Up 8.5 %

NASDAQ BCDA opened at $1.97 on Monday. The stock’s 50-day simple moving average is $2.27 and its two-hundred day simple moving average is $2.30. BioCardia, Inc. has a twelve month low of $1.63 and a twelve month high of $6.15. The company has a market capitalization of $9.22 million, a price-to-earnings ratio of -0.47 and a beta of 1.21.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.62. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. During the same period last year, the business posted ($8.19) earnings per share. On average, equities analysts expect that BioCardia, Inc. will post -3.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCardia

A hedge fund recently bought a new stake in BioCardia stock. CM Management LLC purchased a new stake in shares of BioCardia, Inc. (NASDAQ:BCDA) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 25,000 shares of the company’s stock, valued at approximately $54,000. CM Management LLC owned approximately 0.55% of BioCardia at the end of the most recent reporting period. Institutional investors own 20.57% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Alliance Global Partners raised BioCardia from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 30th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.